Inovio Pharmaceuticals Inc
INO
NASDAQ
Biotechnology
$1.09
USD
+0.19 (+21.10%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $93.07M
Volume 12.1M
Revenue
$0
TTM
-100.0%
YoY
Gross Margin
—
TTM
— YoY
Net Income
$-84.93M
TTM
+12.0%
YoY
Operating Cash Flow
$-83.35M
TTM
+18.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | -100.0% | — | -100.0% | -100.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 9.0 | 8.6 | 7.9 | 7.2 | 7.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 25.1 | 23.1 | 21.2 | 17.5 | 21.9 |
Operating Income | -25.1 | -23.1 | -21.2 | -17.5 | -21.9 |
EBITDA | -24.7 | -22.7 | -20.9 | -17.1 | -21.6 |
Other Income / Expense | 3.9 | -1.0 | -24.8 | 20.8 | 3.9 |
Total Other Income / Expense | 5.4 | -0.4 | -24.3 | 21.2 | 2.3 |
Income Before Income Taxes | -19.7 | -23.5 | -45.5 | 3.8 | -19.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -19.7 | -23.5 | -45.5 | 3.8 | -19.7 |
Consolidated Net Income / Loss | -19.7 | -23.5 | -45.5 | 3.8 | -19.7 |
Net Income Attributable to Common Shareholders | -19.7 | -23.5 | -45.5 | 3.8 | -19.7 |
Basic EPS | -$0.51 | -$0.61 | -$0.87 | $0.06 | -$0.28 |
Diluted EPS | -$0.51 | -$0.61 | -$0.87 | $0.06 | -$0.28 |
Basic Shares Outstanding | 38.6M | 38.8M | 52.2M | 57.9M | 69.1M |
Diluted Shares Outstanding | 38.6M | 38.8M | 52.2M | 57.9M | 69.1M |